Skip to main content
Retour
STOK logo

Stoke Therapeutics, Inc.

Qualité des données : 100%
STOK
NASDAQ Healthcare Biotechnology
32,18 €
▼ 1,22 € (-3,65%)
Cap. Boursière : 1,90B
Fourchette du Jour
31,85 € 33,93 €
Fourchette 52 Semaines
5,35 € 40,22 €
Volume
409 419
Moyenne 50J / 200J
32,73 € / 24,99 €
Clôture Précédente
33,40 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -276,5 0,4
P/B 5,4 2,9
ROE % -2,4 3,9
Net Margin % -3,7 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
42,75 € +32.8%
Low: 35,00 € High: 60,00 €
BPA Prévisionnel
-3,38 €
CA Est.
27 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2029 0,08 €
0,00 € – 0,18 €
340 M 6
FY2028 -2,15 €
-3,43 € – -0,69 €
120 M 8
FY2027 -3,16 €
-3,77 € – -2,05 €
49 M 9

Points Clés

Debt/Equity of 0,00 — conservative balance sheet
Generating 44,92M in free cash flow
Capital efficient — spends only 0,36% of revenue on capex

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)404,50%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-2,37%
ROIC-4,38%
Net Margin-3,73%
Op. Margin-11,16%

Sécurité

Debt / Equity
0,00
Current Ratio5,28
Interest Coverage-1,50

Valorisation

P/E Ratio
-276,47
P/B Ratio5,40
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 404,50% Revenue Growth (3Y) 358,31%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 184,42M Net Income (TTM) -6,89M
ROE -2,37% ROA -1,65%
Gross Margin 100,00% Operating Margin -11,16%
Net Margin -3,73% Free Cash Flow (TTM) 44,92M
ROIC -4,38% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 5,28
Interest Coverage -1,50 Dividend Yield 0,00%
Valuation
P/E Ratio -276,47 P/B Ratio 5,40
P/S Ratio 10,32 PEG Ratio 2,94
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,90B Enterprise Value 1,82B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 184,42M 36,56M 8,78M 12,41M 0,0
Net Income -6,89M -88,98M -104,70M -101,07M -85,81M
EPS (Diluted) -0,12 -1,65 -2,38 -2,60 -2,34
Gross Profit 184,42M 36,56M 8,78M 12,41M 0,0
Operating Income -20,59M -101,37M -114,77M -104,36M -86,07M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 418,43M 271,56M 228,34M 256,07M 238,87M
Total Liabilities 65,98M 42,53M 68,78M 71,22M 21,09M
Shareholders' Equity 352,46M 229,02M 159,57M 184,85M 217,78M
Total Debt 0,0 2,32M 2,06M 2,36M 1,51M
Cash & Equivalents 84,22M 127,98M 191,44M 113,56M 144,90M
Current Assets 305,70M 232,76M 215,34M 244,07M 229,22M
Current Liabilities 57,88M 40,06M 30,82M 31,39M 17,14M